Respiratorius AB (publ)
Research Respiratorius AB (publ) (RESP.ST) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerRESP.ST
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Financial periodQ2 2026
- RevenueSEK 0
- Net income-SEK 1.78M
- Free cash flow-SEK 1.39M
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 30.00K | -SEK 6.95M | -SEK 2.74M | 14470.0% | -1.13 | n/a | n/a | SEK 30.61M |
About Respiratorius AB (publ)
Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company's products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Respiratorius AB (publ) do?
Respiratorius AB (publ), a research company, develops pharmaceuticals for the treatment of cancer. The company's products under development include VAL001, that is in Phase III clinical trials for the treatment of diffuse large B-cell lymphoma; and VAL001, a product candidate that is in preclinical phase for the treatment of relapsing diffuse large B-cell lymphoma. Respiratorius AB (publ) was incorporated in 1998 and is based in Lund, Sweden.